Scale-up and post-approval changes MCQs With Answer (Regulatory Affairs, MPH 104T)
Scaling up a formulation and managing post-approval changes (SUPAC) are pivotal capabilities for M. Pharm students specializing in Regulatory Affairs. This MCQ set simplifies the complex regulatory expectations surrounding process and site changes, equipment and batch-size modifications, excipient and composition changes, and dossier filing strategies across US FDA and EU pathways. You will test your understanding of key guidances such as FDA SUPAC-IR/MR/SS, ICH Q8–Q12, and critical concepts like control strategy, dissolution similarity (f2), BCS-based biowaivers, IVRT, and PACMP. Each question is designed to connect science with regulation—linking CQAs/CPPs, risk management, and validation—to prepare you for real-world submission planning and compliant lifecycle management.
Q1. What is the primary purpose of FDA’s SUPAC guidance for oral dosage forms?
- To replace process validation with real-time release testing
- To provide recommendations for CMC documentation, dissolution, and bioequivalence after post-approval changes
- To harmonize global GMP requirements under ICH
- To eliminate the need for agency review for minor changes
Correct Answer: To provide recommendations for CMC documentation, dissolution, and bioequivalence after post-approval changes
Q2. Which US FDA submission category requires agency approval before distribution of product made with the change?
- Annual Report (AR)
- Changes Being Effected in 0 days (CBE-0)
- Changes Being Effected in 30 days (CBE-30)
- Prior Approval Supplement (PAS)
Correct Answer: Prior Approval Supplement (PAS)
Q3. In dissolution profile comparison, which metric and range typically support similarity between pre- and post-change products?
- f1 between 0 and 15
- f2 between 50 and 100
- AUC ratio between 0.75 and 1.25
- RSD less than 2%
Correct Answer: f2 between 50 and 100
Q4. According to ICH Q12, what tool enables a pre-agreed plan with regulators to manage specific post-approval changes?
- Control strategy
- Bracketing and matrixing
- Post-Approval Change Management Protocol (PACMP)
- Product lifecycle management (PLCM) report only
Correct Answer: Post-Approval Change Management Protocol (PACMP)
Q5. For a modified-release (MR) tablet, which change is generally considered “major” and likely to require a PAS with in vivo BE?
- Increase in batch size using the same equipment and operating parameters
- Change in colorant concentration within established limits
- Change in release-controlling polymer type
- Adding a non-functional film coat of the same composition
Correct Answer: Change in release-controlling polymer type
Q6. Which statement best reflects conditions supporting a BCS Class I biowaiver for post-approval changes?
- Drug is highly soluble, low permeability; rapid dissolution only at pH 1.2
- Drug is highly soluble, highly permeable; rapid dissolution in multiple media and excipients do not affect absorption
- Drug is low solubility, highly permeable; very rapid dissolution in water
- Any drug can qualify if f2 ≥ 50 in one medium
Correct Answer: Drug is highly soluble, highly permeable; rapid dissolution in multiple media and excipients do not affect absorption
Q7. Under SUPAC concepts, changing from a high-shear granulator to a fluid-bed granulator generally represents which type of equipment change?
- Same design and operating principle
- Different design but same operating principle
- Different operating principle
- No change category; always minor
Correct Answer: Different operating principle
Q8. During mixing scale-up of a shear-sensitive suspension, which parameter is commonly targeted to preserve similar shear environment across scales?
- Constant residence time
- Constant power per unit volume
- Constant batch mass
- Constant Reynolds number is never applied in pharma
Correct Answer: Constant power per unit volume
Q9. In the EU Variations system, which category corresponds to “do-and-tell” minor changes with immediate implementation and notification within a defined period?
- Type IA
- Type IB
- Type II
- Extension
Correct Answer: Type IA
Q10. In vitro release testing (IVRT) is especially relevant for assessing post-approval changes in which dosage forms?
- Immediate-release tablets
- Sterile parenterals only
- Semisolid dermatologicals (creams, ointments, gels)
- Hard gelatin capsules only
Correct Answer: Semisolid dermatologicals (creams, ointments, gels)
Q11. Which validation/testing strategy is often used to optimize stability studies when scaling up with multiple strengths or container sizes?
- Concurrent validation only
- Parametric release
- Bracketing and matrixing
- Skip-lot testing
Correct Answer: Bracketing and matrixing
Q12. Which statement best aligns with ICH Q10 change management in the context of SUPAC?
- Changes should be implemented first, then risk assessed
- Risk-based change control links CPPs to CQAs and defines verification/validation needs
- Only QA approves changes; cross-functional science input is discouraged
- Design space eliminates the need for change control
Correct Answer: Risk-based change control links CPPs to CQAs and defines verification/validation needs
Q13. What is a key regulatory benefit of an approved comparability protocol/PACMP?
- It removes all testing requirements for future changes
- It can enable a lower reporting category for pre-defined changes if criteria are met
- It allows unlimited equipment changes without notification
- It replaces bioequivalence studies in every case
Correct Answer: It can enable a lower reporting category for pre-defined changes if criteria are met
Q14. For a non-sterile immediate-release tablet, moving manufacturing to a different building with the same equipment, process, and controls typically aligns with which US FDA reporting pathway (absent other risks)?
- Annual Report (AR)
- Changes Being Effected in 30 days (CBE-30)
- Changes Being Effected in 0 days (CBE-0)
- No reporting required
Correct Answer: Changes Being Effected in 30 days (CBE-30)
Q15. For dissolution profile similarity assessment using f2, what is the minimum number of units per lot typically recommended?
- 6 units
- 10 units
- 12 units
- 24 units
Correct Answer: 12 units
Q16. In which scenario is an in vivo bioequivalence study commonly waived for an IR product after a moderate post-approval change?
- When the API crystal form is changed
- When dissolution similarity (f2) is shown across multiple media and excipients remain within SUPAC-recommended ranges
- When packaging artwork is updated
- When equipment is replaced with a different operating principle
Correct Answer: When dissolution similarity (f2) is shown across multiple media and excipients remain within SUPAC-recommended ranges
Q17. Which change in an MR product is most likely to trigger a PAS due to potential impact on release kinetics?
- Switching to a bottle cap with the same liner material
- Changing from a hydrophilic matrix to a membrane-coated reservoir system
- Reducing overage of a non-functional excipient within range
- Adding a flavor within IIG limits
Correct Answer: Changing from a hydrophilic matrix to a membrane-coated reservoir system
Q18. Following a significant manufacturing change, how many consecutive commercial-scale PPQ batches are typically expected to demonstrate process performance qualification?
- 1 batch
- 2 batches
- 3 batches
- 5 batches
Correct Answer: 3 batches
Q19. For an IR tablet, changing to a different grade of a compendial excipient (same manufacturer) without functional change most commonly aligns with which reporting category?
- Prior Approval Supplement (PAS)
- Changes Being Effected in 30 days (CBE-30)
- Annual Report (AR)
- No reporting required globally
Correct Answer: Annual Report (AR)
Q20. Which risk management approach from ICH Q9 is most appropriate to justify testing scope and filing strategy during scale-up?
- Fishbone diagram only, without data
- Failure Mode and Effects Analysis (FMEA) linking CPPs to CQAs and control strategy
- 100% end-product testing in place of risk assessment
- Supplier audit alone
Correct Answer: Failure Mode and Effects Analysis (FMEA) linking CPPs to CQAs and control strategy
